Endocyte | search
Click here to view Endocyte news from 60+ newspapers.
Bookmark or Share- ASCO: Novartis backs up $2.1B Endocyte buyout with prostate cancer dataMore than two years after splashing out $2.1 billion on Endocyte, Novartis is pulling the curtain on full phase 3 data for the radiopharmaceutical it picked up in that deal.
- Novartis successfully completes acquisition of EndocyteBasel, December 21, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment.
- Endocyte starts renaissance by licensing ‘billion-dollar’ prostate ...A few months ago, Endocyte was shedding R&D programs and staff, with questions being raised about its future. Now, it says its prospects have been resurrected by licensing a phase 3-ready...
- Novartis inks $2.1B Endocyte buyout, furthering radiotherapy pushNovartis has struck a $2.1 billion (€1.8 billion) deal to acquire Endocyte. The deal caps off a whirlwind year for Endocyte, which licensed the cancer drug that caught Novartis’ eye for $12 ...
- Purdue startup Endocyte sold in $2.1B deal with NovartisPurdue startup Endocyte sold in $2.1B deal with pharmaceutical giant Novartis. Endocyte, based in West Lafayette, has been chasing a targeted drug to cure prostate cancer. Novartis deal...
More
